Hot on the heels of a $150 million fundraise, Atsena Therapeutics is back with early-stage data for the company’s eye disease ...

Pacibekitug, an antibody targeting interleukin-6, hit the primary endpoint in the phase 2 Tranquility trial by sharply ...

Apellis Pharmaceuticals focuses on creating medicines targeting eye diseases and rare neurological diseases. Read why I rate ...

Amidst global trade tensions, at least five companies from mainland China and Hong Kong are planning IPOs, dual listings, or ...

Channel Therapeutics reports CT2000 reduced eye pain in preclinical trials, with plans to enter human testing for acute and ...

At least five companies from mainland China or Hong Kong are planning IPOs, dual listings, or share placements in Singapore in the next 12 to 18 months, four sources said, as Chinese firms look to ...

At least five Chinese and HK firms eye listings on SGX. Read more at straitstimes.com. Read more at straitstimes.com.

The Institute for Clinical and Economic Review (ICER) has released a Final Evidence Report assessing the comparative clinical effectiveness and value of sonpiretigene isteparvovec for the treatment of ...

Norwich Research Park biotech company, Ikarovec, has appointed ophthalmology drug development specialist Dr Thomas Ciulla as ...

Discover the charm of classic woodworking that can elevate any home to timeless elegance! 🏡✨ From intricate moldings to stunning built-ins, these features are the perfect blend of craftsmanship and ...